Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Liabilities: 2018-2025

Historic Other Non-Current Liabilities for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $1.1 million.

  • Bicycle Therapeutics' Other Non-Current Liabilities fell 81.67% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 81.67%. This contributed to the annual value of $1.1 million for FY2024, which is 75.52% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Other Non-Current Liabilities of $1.1 million as of Q3 2025, which was down 4.04% from $1.1 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Other Non-Current Liabilities high stood at $6.0 million for Q3 2024, and its period low was $1.1 million during Q3 2025.
  • In the last 3 years, Bicycle Therapeutics' Other Non-Current Liabilities had a median value of $4.3 million in 2023 and averaged $3.4 million.
  • In the last 5 years, Bicycle Therapeutics' Other Non-Current Liabilities spiked by 42.01% in 2021 and then slumped by 81.67% in 2025.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Other Non-Current Liabilities stood at $3.3 million in 2021, then grew by 16.77% to $3.8 million in 2022, then rose by 19.59% to $4.6 million in 2023, then tumbled by 75.52% to $1.1 million in 2024, then plummeted by 81.67% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.